<SEC-DOCUMENT>0001213900-26-040185.txt : 20260406
<SEC-HEADER>0001213900-26-040185.hdr.sgml : 20260406
<ACCEPTANCE-DATETIME>20260406092035
ACCESSION NUMBER:		0001213900-26-040185
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260406
FILED AS OF DATE:		20260406
DATE AS OF CHANGE:		20260406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		26839734

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0285169-6k_neuro.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer Pursuant to Rule
13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of April 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.<BR>
</B>(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9-7996183<BR>
</B>(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Explanatory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 6, 2026, NeuroSense
Therapeutics Ltd. issued a press release entitled &ldquo;NeuroSense Granted Brazilian Patent Covering PrimeC Composition.&rdquo; A copy
of the press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The first two paragraphs
of the press release attached hereto as Exhibit 99.1 are hereby incorporated by reference into the registrant&rsquo;s Registration Statements
on Form S-8 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm">333-262480
</A>and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390025077513/ea0252622-s8_neurosense.htm">333-289658</A>) and Form
F-3 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm">333-269306</A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm">333-260338</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024106506/ea0223814-f3_neuro.htm">333-283656</A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024112695/ea0226024-f3_neurosense.htm">333-284051</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390025103109/ea0262630-f3_neurosense.htm">333-291122</A>
and <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390026009643/ea0274510-f3_neurosense.htm">333-293060</A>) to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea028516901ex99-1.htm">Press Release dated April 6, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NeuroSense Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: April 6, 2026</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028516901ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED APRIL 6, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Granted Brazilian Patent Covering
PrimeC Composition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Patent Protection Through October 2042</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Follows prior patent grants in the U.S. and Australia</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Further strengthens NeuroSense&rsquo;s global intellectual property portfolio</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CAMBRIDGE, Mass.,&nbsp;April. 6, 2026&nbsp;/PRNewswire/
--&nbsp;NeuroSense Therapeutics Ltd.&nbsp;(Nasdaq: NRSN) (&ldquo;NeuroSense&rdquo;
or the &ldquo;Company&rdquo;), a late-clinical stage biotechnology company developing novel treatments for&nbsp;severe neurodegenerative
diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled
&ldquo;Compositions Comprising Ciprofloxacin and Celecoxib.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028516901_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The granted Brazilian patent, following prior
approval of the corresponding U.S. patent (12,097,185) and Australian patent (2022370513), provides protection for NeuroSense&rsquo;s
proprietary PrimeC composition in Brazil and extends patent coverage through October 2042, further strengthening the Company&rsquo;s global
intellectual property estate and supporting the long-term development and potential commercialization of PrimeC in ALS, Alzheimer&rsquo;s
disease and additional neurodegenerative indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This patent grant further reinforces the
strength and durability of our intellectual property strategy around PrimeC,&rdquo; said Alon Ben-Noon, Chief Executive Officer of NeuroSense.
&ldquo;Securing composition-of-matter protection in Brazil is another important step in expanding our global IP footprint as we advance
PrimeC toward pivotal development and potential commercialization.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PrimeC is a proprietary fixed-dose oral therapy
combining ciprofloxacin and celecoxib in a synchronized, extended-release formulation specifically targeted to deliver both agents in
a coordinated manner - a key differentiator versus simple co-administration. The formulation is designed to enable consistent exposure
across multiple disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting
a multi-target disease-modifying approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are preparing for initiation of a Phase 3
pivotal clinical trial for PrimeC in ALS (PARAGON), following positive Phase 2b PARADIGM results and clearance from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
NeuroSense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">NeuroSense
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include </FONT>amyotrophic lateral sclerosis <FONT STYLE="background-color: white">(ALS),
Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple
pathways associated with these diseases. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">For additional
information, we invite you to visit our&nbsp;</FONT><FONT STYLE="background-color: white">website</FONT><FONT STYLE="background-color: white">&nbsp;and
follow us on&nbsp;</FONT><FONT STYLE="background-color: white">LinkedIn</FONT><FONT STYLE="background-color: white">,
</FONT><FONT STYLE="background-color: white">YouTube&nbsp;</FONT><FONT STYLE="background-color: white">and&nbsp;</FONT><FONT STYLE="background-color: white">X</FONT><FONT STYLE="background-color: white">.
Information that may be important to investors may be routinely posted on our website and these social media channels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
PrimeC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">PrimeC,
NeuroSense&rsquo;s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved
drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute
to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit
the progression of ALS and AD. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
ALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Amyotrophic
lateral sclerosis (&ldquo;ALS&rdquo;) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years
from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of&nbsp;$1
billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>About Alzheimer&rsquo;s Disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B></B>Alzheimer&rsquo;s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting
more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has
no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments
that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such
as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Forward-Looking
Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by
the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; &ldquo;would,&rdquo;
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on NeuroSense Therapeutics&rsquo; current expectations and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict and include statements regarding the PrimeC pivotal trial. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk
that we do not complete in a timely fashion the PrimeC pivotal trial, and that the single pivotal trial will not be sufficient to support
a New Drug Application submission; uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes
and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for
reporting data, including from the study of PrimeC in Alzheimer&rsquo;s disease; that the study will not be successful; the ability of NeuroSense
to remain listed on Nasdaq; the going concern reference in our financial statements and our need for substantial additional financing
to achieve our goals; and other risks and uncertainties set forth in NeuroSense&rsquo;s filings with the Securities and Exchange Commission
(SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties
affecting NeuroSense is contained under the heading &ldquo;Risk Factors&rdquo; in the Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 31, 2026 and NeuroSense&rsquo;s subsequent filings with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">For further
information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028516901_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028516901_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Y <H# 2(  A$! Q$!_\0
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MJ7A35[;_ (\VU2U']EZB/^H"PS_PD .",C/IW(/YO5PN:9;+GJ-J$FW3:?\
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M /@CZRK^T+^T &X#?VJOO_R.<AX]^*_3[]O']D'1OVGOA9+;VIM]/\?^&/\
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M<\]"%ST!-?S7?M'?\$<_BQ\.4U'7_@QXB?XBZ!;%KQ/#VL#'B2S Q]QU)'B
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MPROV7Q)Q_P 2+Q.F!K ;.?F5O-P ,<C&,5_,%^UEX0_:+^'/Q%G\ _M!^/\
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M+/\ X*@_L3_\)II<WQT^&6F >.M!L_,\0:59VH#>+M+!).% 7_B?IE0DF#N
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MG,<;@>.ZCH\L:SR"*2JJ5=S;HZN%W^[E%J+37*[I=/Q:^ G_  1UMIGL]?\
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MHW)2H>QIKE5/57DM;WM_+9?>5Y^WX?UK\2/VPOV=?&O[4O\ P4)^!_@#4O\
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M4=2%%2U<5/7S?+_D>1A<,E6K:+>%O+XF>=? +4M7USX,_"_5/$-AJ&EZU=^
M_"[ZMI>K#_B96&HC1X1,'_Z:-DX.,X (.0P.U\3-"TO6O GB^WU72]-U.#_A
M&?$A-MJEFNHH0VCR<!6+$#Y<'!+8*[>AKOH._P"/]*YOQC_R)WB__L7]9_\
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M_/E_P47_ &0OAEX&_;^_97TKP!_;O@@_M ^)=4O/&7B&UU5M0U/3]5_MG/\
M;.A%P#H(7IN4E2P(!!! _5WXI_\ !(C]C?QQ\*M5\$:'\,[31/$YMFO=)^('
MVF0^*3XD96,6M:[K1VMK;CY3()%88##Y2P(WG2C*,/GOZ1\CBAB?>GK:UNOK
MYK^K=S]2=.U+3]5M(;_3+VVO["Z3-I=VEX-1L+M2"<B12PSD'[K;1@C=Q6IY
MPR3CD^W_ ->OYZ_^"(/Q?^(D=S^T%^RC\0-<NO$4'P)\0LGAN_U.\&HR:=I/
M]L_V'_8H?J,$97/&[&:_H3R$&.>?3G_#VK&=+V<XJV][Z><;=$=$,1>,WO:V
MN]M_-GGGQ$^*G@#X3Z%/XI^)GC'P[X*\.VXPVK>(+Y-.C'?G<=QSC&$_$#//
MF?PF_:K_ &?/CC>7.F?"[XJ>&_%VM6H(O-!L[MK'5P#V71=;6&4^X50>ISS7
M\[VJ?M-_";XY?\%$?B_XI_:DLO%?C/X0?L^WVI>#/A!\,[;1?^$E\,?\)-H3
M@R>,];T)60:^[H'"MDA7(D99 "C5OV[?C5\ _%%_\$?C3^QY\/?B#X5^._P[
M\>Z5?75WX4^&VK>&FUSPN1@Z'K90*"O&1N!<$L"[#:$VE%*,?._ILMO/77\#
MC^LKVGS_ *_KL?U<F0&,-W''MCK_ "Y_KFLO5-8TG0+-K_6=3T_2+)!M^UZG
M>Q:=9 GD#=,ZJ..H8CU%<]X0UB]U_P )^$]=N;<6FH:[X=TC6[NWX)L]0U?1
M4ESCT5W=".WS9QFN:^,WP9\#_'?X?Z]\,_B-8W.H^$-?4"^L[2Z:P8@#@;U[
M*Q)R002QQM))K/EZ=+W_ . >A]8]S;6WS#P;\;/A7\2-<U_P[X"\?>'/%>L>
M%L?\))9:!JZ:D^FDX&&*%DW9_N$KC@$]:J>/?CM\'OAC'L\>?$SP9X<G-R+(
M6U]KNE)JIU,]5.D;FN%?ODJ2,;2<DX_"K_@BWX$T+X>?M+_M]^#_  [ EMHW
M@SQWI?AK1K63_D(#3$^=6<@C"JR@G'/7%<M_P6X_9F^$O@P_"CX_:'H5W:?$
MCQW\=M(L?$NJ-=-J.FWNG%=Y!T0@(Q"LO"$A3G)Z"G;;R.-8GW*S\X^G7^OZ
MU_I6MKN"_M+>\LYA<6MU:BYMKG.X.I QCIQ@@XQZ@].<?Q+XET3P=HNJ^(?$
M6JV&B>']#LSJNKZOJET+#3=.TY5;,CN<J NPC+#!<A>7=4JA\/8P/ /@F+LO
MA#PP#V_Y@T(X_'_]>:G\8>"O"WQ!\,ZEX1\<:)IOB7PQKMH;/5_#^K1B_P!.
MOHP =KB3:3CD'&P], $&LY?'!=N;\7$[Y3Y\%?KRZ_=I]_\ 6Y^4WP1_X*Z?
M CXR?'7XD^#6\2^'/!GPA\':/IJ^&?B)XKO#IG_"=^)/,)UG^PT9G1M!ACVJ
M)7&]RFXD!B!^H?P[^+/PW^+.AW'B3X:>,="\;:#;W9L;G5O#]V-1T]=0 4E-
MRD\*3G"MUQUQNK^=']@?]GSX$^.OV_/V\?!'C#X5^"?$GA#P%K.E?\(=X>U?
M2%O]+T'YAG^Q-%8,%&WKP3C[HW;:_HG^&WPF^&/P9T!O#7PM\$>&_ .@7%T;
MTZ3X?LQIVG-J7]XJ@ ^;# 87GD 8.!I6M:GZ/\D<F'^#^N[._O9[>WMII;V:
MWMK(*?M5U=7)L N!CER%"C Q\SIGH,U\&Z)\/?V#[[]JFW^(WAZ#X87W[2^I
MVFHD7NE:Q%J6KL0VZ36"%,D8UXKB,$-YF"^"&5)&^VO%/A?2?&WAS6?"VNP2
MW6CZ]8MI&J6N1S&<$G.#QG!)!*D;6QFOYJ?V=?@'\/O@#_P6OUCX>> -*N=-
M\*Z7\*-4UW2+:ZO/[1^P:EKJ[B1G!' XR<CJ<'K$/AGOT_)FDZGLY0_O-_A;
M_,_IS\H?Z[\,^W3.?\_7M1YUOGS\C^N.N,?3BIL_(1V _7:/Z&OQ/_X+(_M*
M>-_A3\-?AQ\&OA=KESX=\7_'_P 9Z5X*U+Q%IA;3]6T[PQK6JB*1]%UH@+%/
MO,T;[ <IQD>8Z5G17OU/2/W-R-:^(M&GK;1_C;3==F???C;]NG]DOX?Z]/X6
M\5_'7P%IFMVMT+2[L6U 7S6,F#Q*T&].P!9"ZCG ( S]'^%/%_A;QYX?L?$_
M@_Q#I/B3P_J8S8ZKI%VFH:=>J>"$D1MN1C(!(;U!!&?@;P3_ ,$U/V7+/]G2
M+X'Z[\--%U&TUWP\B^+/%-X!?^-=2\2,J%M;;7V5G:57\PJ$*H5V(5SODKU/
M]BC]CWPS^Q1\*=0^$OA#Q5XC\6:+<^)=7\465UXC*DV(U=U)TI<,?D1@&P1N
M^Z2%X#:35DOQ,J51U*L-;I7ZWM>WFS[,,ORX Z=,C^?/O7RQ\2/VS_V8OA)K
MDOA/QW\8O".BZ[;C%]IMOJ#ZE/I:[?E.M?V+%.=%?).X3&+;U.X_*/6OB[:>
M*[SX5_$"S\!.EOXNNO!OB5/#;= =;_LF1-' [C+B-<#^(8]J_F"_X)>_'?\
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MXE^(.D9_X0;3VV!&T4:Z6/\ Q4!V@JNT%?FR6+<?T1?%_P#9R^!WQWM8=/\
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ME<>H4\L"ZKD>U44!3Z_+]0HHHH- HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
